Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Experiencia en ingeniería de partículas para optimizar la administración de medicamentos por vía inhalatoria

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20160707002
Publicado:
11/07/2016
Caducidad:
11/07/2017
Resumen:
Una compañía farmacéutica británica está especializada en aplicaciones de ingeniería de partículas y cristales para fluidos supercríticos que permiten diseñar terapias nuevas y más eficaces. La tecnología ofrece ventajas en cuanto a la ingeniería de partículas aerodinámicas para formulaciones administradas por vía inhalatoria o nasal, lo que se traduce en un rendimiento superior del producto. La tecnología de fluidos supercríticos es innovadora porque las características de las partículas pueden configurarse desde el principio, incluyendo la capacidad para modificar la forma de estado sólido, tamaño, forma, morfología y propiedades superficiales. La empresa busca socios interesados en optimizar el diseño de partículas o aumentar la eficacia de productos respiratorios mediante acuerdos de licencia y desarrollo conjunto.


Details

Tittle:
Particle engineering expertise for optimised inhaled drug delivery
Summary:
A UK SME specialises in applications of supercritical fluid (SCF) crystal and particle engineering technology to enable the design of new and more effective therapies. The technology has a distinct advantage when it comes to engineering aerodynamic particles for inhaled or nasal formulations, resulting in superior product performance. Partners wishing to optimise particle design or seeking to enhance efficacy of respiratory products are sought for license and/or co-development agreements.
Description:
Therapeutic drug administration by inhalation is a rapidly growing area in the pharmaceutical industry. There are an increasing number of new and improved drugs for respiratory disease, and companies are also evaluating the benefits afforded by pulmonary drug delivery (e.g. faster onset of action, capable of delivering medicines both locally and systemically and more patient-friendly). Tight control of particle size and morphology is essential to optimising the performance of inhaled formulations.
A UK-based SME specialises in applications of the latest supercritical fluid (SCF) crystal and particle engineering technology to pharmaceutical product development.
The SCF process has intrinsic advantages over conventional size reduction and spray drying approaches to inhaled product development. Based on a ´bottom-up´ single step approach, crystals and particles are formed from a dissolved solution, typically with low levels of electrostatic charge, fewer crystal defects/amorphous hotspots, as well as a targeted particle size and tight particle size distribution. This results in strong aerodynamic performance compared with particles generated using other technologies and the potential for greatly enhanced deep lung delivery when required. Partners wishing to optimise particle design or seeking to enhance efficacy of respiratory products are sought for license and/or technical cooperation for co-development agreements.
Advantages and Innovations:
The team includes leading experts, who have helped design the world´s first SCF-based medicine, an inhaled treatment for migraine, which is currently awaiting final FDA review.
SCF technology is innovative because the characteristics of the particle can be fine-tuned from the outset including the ability to modify the solid state form, size, shape, morphology and surface properties. In recent data generated, SCF powders were able to achieve a fine particle fraction three times greater than achieved with micronised material. A particular advantage of SCF engineered particles is their suitability for use in a wide range of proprietary and off-the-shelf inhaler devices, and the opportunity to create simplified formulations requiring fewer excipients. SCF particles can be aerosolised at low pressure without the need for suspending agents. SCF is a thermodynamically stable process and when it has been optimised, it is highly reproducible, achieving yields above 95% which combined with the need for fewer excipients can greatly reduce the cost of goods of respiratory medicines. The team has extensive experience in designing inhalable dosage formulations.
Stage of Development:
Already on the market
IPs:
Exclusive rights

Partner sought

Type and Role of Partner Sought:
The company is looking to partner with SMEs, research and development organisations, universities, not-for-profit companies or foundations, and large companies from the pharmaceutical industry. Partners would typically be seeking to develop an optimised new inhaled medicine, or repurposing a therapy for inhalation wishing to optimise particle design or seeking to enhance efficacy of respiratory products are sought for license and/or technical cooperation for co-development agreements.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
06002009 Diseño molecular
05005 Micro y nanotecnología
06004 Micro y nanotecnología relacionada con las ciencias biológicas
06002008 Microbiología
05004006 Otros procesos